Vitamin K2, MK-4 vs. MK-7: A Formulator's FAQ

Vitamin K2 has moved from a relatively obscure nutrient to a near-default cofactor in bone and cardiovascular health formulations, with new clinical research continuing to expand its potential applications.

But not all forms of K2 are created equal, and the two commercially dominant forms, MK-4 and MK-7, differ meaningfully in dosing, bioavailability, and the depth of clinical evidence behind them.

The FAQ below walks through what formulators need to understand before building a K2-containing product.

What Is the Basic Difference Between MK-4 and MK-7?

Both menaquinone-4 (MK-4) and menaquinone-7 (MK-7) are forms of vitamin K2, distinguished primarily by the length of their isoprenoid side chain and, as a result, their pharmacokinetics in the body.

MK-7 is more readily absorbed and has a substantially longer half-life than MK-4, allowing it to remain active in circulation for an extended period and produce measurable effects at microgram-level doses, while MK-4 requires higher and more frequent dosing, typically in the milligram range, to achieve comparable activity.¹

Why Does Vitamin K2 Matter for Bone and Cardiovascular Health?

Vitamin K2 activates vitamin K-dependent proteins through a process called carboxylation, most notably osteocalcin, which helps bind calcium to bone, and matrix Gla protein, which inhibits calcium deposition in soft tissues such as arteries.¹

This dual mechanism is part of why K2 has drawn interest in both bone health and cardiovascular health formulations: it is positioned not only to support calcium deposition where it belongs, in bone, but also to help prevent calcium accumulation where it does not belong, in arterial walls.

What Does the Most Recent Clinical Research Show for MK-7 Specifically?

A 2026 randomized controlled trial published in JAMA Cardiology found that a daily dose of 360 mcg of MK-7 over 24 months was associated with approximately 29% less progression of coronary artery calcification in patients with existing coronary artery disease, compared with placebo.²

The trial also found a comparable reduction in calcium mass score, a separate and more precise measure of calcification progression, reinforcing the finding. This represents 1 of the more rigorously designed trials to date examining MK-7's role specifically in vascular calcification, an application distinct from, though mechanistically related to, its more established role in bone health.

Separately, a March 2025 case study examined MK-7 supplementation in a kidney disease patient with calciphylaxis, a serious condition involving calcium buildup in small blood vessels that is associated with low vitamin K status in hemodialysis patients.³

While a single case study cannot establish broad efficacy, it points to an area of continued clinical interest in MK-7's vascular calcification-related applications beyond the general population.

Why Have MK-4 Doses Historically Been So Much Higher Than Mk-7 Doses?

The dosing gap between the 2 forms reflects MK-4's comparatively lower bioavailability and shorter half-life relative to MK-7, meaning substantially more material is needed to achieve comparable biological activity.¹

This is one of the most important practical distinctions for formulators, since a mg-level dose of MK-4 takes up considerably more capsule or tablet volume than a microgram-level dose of MK-7, a factor that has contributed to MK-7 becoming the more commonly used form in newer commercial formulations.

How Should Formulators Think About Choosing Between MK-4 and MK-7?

The choice often comes down to formulation goals, target dose, and the specific clinical claim being pursued. MK-7's lower effective dose and longer half-life make it easier to incorporate into a multi-ingredient formula without contributing significant bulk, and it currently carries the more active pipeline of new clinical research, including the cardiovascular calcification work noted above.²

MK-4 may still be relevant for formulators targeting specific bone-health claims tied to its longer-established use, though the higher dosing requirement remains a practical formulation constraint.¹

What Should Manufacturers Keep in Mind About Extrapolating Clinical Findings Across Populations?

The 2026 coronary artery calcification trial was conducted in a symptomatic population with existing coronary artery disease, the majority of whom were also on statin therapy, and should not be assumed to generalize directly to healthy adults without cardiovascular risk factors.²

Similarly, the calciphylaxis case study involved a single patient with significant kidney disease, a population with distinct vitamin K metabolism compared with the general population.³ As with any nutraceutical ingredient, manufacturers should match the population, dose, and outcome measure in their claims substantiation to what was actually studied, rather than extrapolating findings from a specific patient population to a general wellness claim.

References

1. Krawiec S. Spotlight on vitamin K2. Nutritional Outlook. March 14, 2024. Accessed June 30, 2026. https://www.nutritionaloutlook.com/view/spotlight-on-vitamin-k2

2. Saraceno N. Two-year trial shows vitamin K2 slowed coronary artery calcification progression. Nutritional Outlook. June 12, 2026. Accessed June 30, 2026. https://www.nutritionaloutlook.com/view/two-year-trial-shows-vitamin-k2-slowed-coronary-artery-calcification-progression

3. McEvoy E. Case study shows effects of vitamin K2 supplementation for calciphylaxis in kidney disease patient. Nutritional Outlook. March 12, 2025. Accessed June 30, 2026. https://www.nutritionaloutlook.com/view/case-study-shows-effects-of-vitamin-k2-supplementation-for-calciphylaxis-in-kidney-disease-patient